Compare Amylx Pharmaceuticals Inc (AMLX) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $30.23. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | QDTE | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $18.70 | $36.60 |
52-Week Low | $7.64 | $26.85 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
QDTE trades at $30.495, up 0.35% on the day, with a bearish technical outlook from moving averages and a neutral signal from oscillators. The ETF focuses on weekly dividend distributions from a 0DTE covered call strategy on a synthetic Nasdaq portfolio, attracting income investors. Recent news highlights its high distribution yield, though volatility has declined.
The outlook remains cautious due to technical bearishness and reliance on options income, which is sensitive to market volatility. Risks include yield compression from lower volatility and competitive pressure from similar ETFs. Analyst sentiment is mixed, emphasizing yield attractiveness but noting total return underperformance versus benchmarks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
